0000059478-22-000233.txt : 20221012 0000059478-22-000233.hdr.sgml : 20221012 20221012160843 ACCESSION NUMBER: 0000059478-22-000233 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20221012 ITEM INFORMATION: Other Events FILED AS OF DATE: 20221012 DATE AS OF CHANGE: 20221012 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ELI LILLY & Co CENTRAL INDEX KEY: 0000059478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 350470950 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-06351 FILM NUMBER: 221306944 BUSINESS ADDRESS: STREET 1: LILLY CORPORATE CTR STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 BUSINESS PHONE: 3172762000 MAIL ADDRESS: STREET 1: LILLY CORPORATE CENTER STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 FORMER COMPANY: FORMER CONFORMED NAME: LILLY ELI & CO DATE OF NAME CHANGE: 19941024 8-K 1 lly-20221012.htm 8-K lly-20221012
0000059478false00000594782022-10-122022-10-120000059478us-gaap:CommonClassAMember2022-10-122022-10-120000059478lly:A718NotesDueJune12025Member2022-10-122022-10-120000059478lly:A1.625NotesDueJune22026Member2022-10-122022-10-120000059478lly:A2.125NotesDueJune32030Member2022-10-122022-10-120000059478lly:A625Notesdue2031Member2022-10-122022-10-120000059478lly:A500NotesDue2033Member2022-10-122022-10-120000059478lly:A6.77NotesDueJanuary12036Member2022-10-122022-10-120000059478lly:A1625NotesDue2043Member2022-10-122022-10-120000059478lly:A1.700Notesdue2049Member2022-10-122022-10-120000059478lly:A1125NotesDue2051Member2022-10-122022-10-120000059478lly:A1375NotesDue2061Member2022-10-122022-10-12

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): October 12, 2022
ELI LILLY AND COMPANY
(Exact Name of Registrant as Specified in its Charter) 
Indiana 001-06351 35-0470950
(State or Other Jurisdiction
of Incorporation)		 (Commission
File Number)		 (I.R.S. Employer
Identification No.)
  


Lilly Corporate Center
Indianapolis,Indiana46285
(Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (317) 276-2000

Not Applicable
(Former Name or Former Address, if Changed Since Last Report.) 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock (no par value)LLYNew York Stock Exchange
7 1/8% Notes due 2025LLY25New York Stock Exchange
1.625% Notes due 2026LLY26New York Stock Exchange
2.125% Notes due 2030LLY30New York Stock Exchange
0.625% Notes due 2031LLY31New York Stock Exchange
0.500% Notes due 2033LLY33New York Stock Exchange
6.77% Notes due 2036LLY36New York Stock Exchange
1.625% Notes due 2043LLY43New York Stock Exchange
1.700% Notes due 2049LLY49ANew York Stock Exchange
1.125% Notes due 2051LLY51New York Stock Exchange
1.375% Notes due 2061LLY61New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐






Item 8.01 Other Events.

Estimated Third Quarter Acquired In-Process Research and Development (“IPR&D”) and Development Milestone Charges

Eli Lilly and Company (“Lilly”) currently expects that its reported financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”) and its non-GAAP financial results for the third quarter of 2022 will include acquired IPR&D and development milestone charges of approximately $62.4 million on a pre-tax basis, representing a charge of $0.06 to both GAAP and non-GAAP earnings per share. Lilly’s results for the quarter ended September 30, 2022 have not been finalized and are subject to Lilly’s financial statement closing procedures. There can be no assurance that actual results will not differ from the preliminary estimates described herein.

As previously disclosed, while acquired IPR&D and development milestone charges may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, Lilly does not forecast acquired IPR&D and development milestone charges due to the uncertainty of the future occurrence, magnitude, and timing of these transactions in any given period.

Lilly Website Notice

Lilly routinely posts important information for investors in the “Investors” section of its website, www.lilly.com. Lilly may use its website as a means of disclosing material, non-public information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the “Investors” section of Lilly’s website, in addition to following its press releases, filings with the Securities and Exchange Commission (“SEC”), public conference calls, presentations, and webcasts. Lilly may also use social media channels to communicate with investors and the public about its business, products and other matters, and those communications could be deemed to be material information. The information contained on, or that may be accessed through, Lilly’s website or social media channels, is not incorporated by reference into, and is not a part of, this Current Report on Form 8-K.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contains management’s current intentions and expectations for the future, including with respect to Lilly’s anticipated acquired IPR&D and development milestone charges for the quarter ended September 30, 2022, and the related impact to Lilly’s GAAP and non-GAAP earnings per share, all of which are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ due to various factors, including those discussed in Lilly’s latest Annual Report on Form 10-K and subsequent filings with the SEC, and additional procedures Lilly will undertake to finalize its results for the period that could result in changes to Lilly’s preliminary estimates described herein. For additional information, please see Lilly’s filings with the SEC. Investors should not place undue reliance on forward-looking statements, which speak only as of the date of this Current Report on Form 8-K. Except as is required by law, Lilly expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this Current Report on Form 8-K.





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ELI LILLY AND COMPANY
(Registrant)
By:/s/ Donald A. Zakrowski
Name:Donald A. Zakrowski
Title:Senior Vice President, Finance, and Chief Accounting Officer
Date: October 12, 2022

 EX-101.SCH 2 lly-20221012.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 lly-20221012_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 4 lly-20221012_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, Postal Zip Code Entity Address, Postal Zip Code 1.125% Notes due 2051 1.125% Notes due 2051 [Member] 1.125% Notes due 2051 1.625% Notes due 2043 1.625% Notes due 2043 [Member] 1.625% Notes due 2043 1.625% Notes due 2026 1.625% Notes Due June 2, 2026 [Member] 1.625% Notes Due June 2, 2026 [Member] 1.700% Notes due 2049 1.700% Notes due 2049 [Member] 1.700% Notes due 2049 [Member] 1.375% Notes due 2061 1.375% Notes due 2061 [Member] 1.375% Notes due 2061 Document Period End Date Document Period End Date 6.77% Notes due 2036 6.77% Notes Due January 1, 2036 [Member] 6.77% Notes Due January 1, 2036 [Member] Entity Central Index Key Entity Central Index Key 7 1/8% Notes due 2025 7 1/8% Notes Due June 1, 2025 [Member] 7 1/8% Notes Due June 1, 2025 [Member] 2.125% Notes due 2030 2.125% Notes Due June 3, 2030 [Member] 2.125% Notes Due June 3, 2030 [Member] Document Information [Table] Document Information [Table] Entity Emerging Growth Company Entity Emerging Growth Company Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security .500% Notes due 2033 .500% Notes due 2033 [Member] .500% Notes due 2033 Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Written Communications Written Communications Local Phone Number Local Phone Number Soliciting Material Soliciting Material Entity Address, State or Province Entity Address, State or Province City Area Code City Area Code Document Type Document Type Document Information [Line Items] Document Information [Line Items] Class of Stock [Domain] Class of Stock [Domain] Entity Incorporation, Date of Incorporation Entity Incorporation, Date of Incorporation Common Stock (no par value) Common Class A [Member] Cover [Abstract] Cover [Abstract] Entity Address, City or Town Entity Address, City or Town Class of Stock [Axis] Class of Stock [Axis] Pre-commencement Tender Offer Pre-commencement Tender Offer Entity File Number Entity File Number 0.625% Notes due 2031 .625% Notes due 2031 [Member] .625% Notes due 2031 [Member] Amendment Flag Amendment Flag Trading Symbol Trading Symbol Entity Tax Identification Number Entity Tax Identification Number EX-101.PRE 5 lly-20221012_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover Page
Oct. 12, 2022
Document Information [Line Items]  
Document Type 8-K
Document Period End Date Oct. 12, 2022
Entity Incorporation, State or Country Code IN
Entity File Number 001-06351
Entity Tax Identification Number 35-0470950
Entity Address, Address Line One Lilly Corporate Center
Entity Address, City or Town Indianapolis,
Entity Address, State or Province IN
Entity Address, Postal Zip Code 46285
City Area Code 317
Local Phone Number 276-2000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Registrant Name ELI LILLY AND COMPANY
Entity Central Index Key 0000059478
Amendment Flag false
Entity Emerging Growth Company false
Common Stock (no par value)  
Document Information [Line Items]  
Title of 12(b) Security Common Stock (no par value)
Trading Symbol LLY
Security Exchange Name NYSE
7 1/8% Notes due 2025  
Document Information [Line Items]  
Title of 12(b) Security 7 1/8% Notes due 2025
Trading Symbol LLY25
Security Exchange Name NYSE
1.625% Notes due 2026  
Document Information [Line Items]  
Title of 12(b) Security 1.625% Notes due 2026
Trading Symbol LLY26
Security Exchange Name NYSE
2.125% Notes due 2030  
Document Information [Line Items]  
Title of 12(b) Security 2.125% Notes due 2030
Trading Symbol LLY30
Security Exchange Name NYSE
0.625% Notes due 2031  
Document Information [Line Items]  
Title of 12(b) Security 0.625% Notes due 2031
Trading Symbol LLY31
Security Exchange Name NYSE
6.77% Notes due 2036  
Document Information [Line Items]  
Title of 12(b) Security 6.77% Notes due 2036
Trading Symbol LLY36
Security Exchange Name NYSE
1.700% Notes due 2049  
Document Information [Line Items]  
Title of 12(b) Security 1.700% Notes due 2049
Trading Symbol LLY49A
Security Exchange Name NYSE
.500% Notes due 2033  
Document Information [Line Items]  
Title of 12(b) Security 0.500% Notes due 2033
Trading Symbol LLY33
Security Exchange Name NYSE
1.625% Notes due 2043  
Document Information [Line Items]  
Title of 12(b) Security 1.625% Notes due 2043
Trading Symbol LLY43
Security Exchange Name NYSE
1.125% Notes due 2051  
Document Information [Line Items]  
Title of 12(b) Security 1.125% Notes due 2051
Trading Symbol LLY51
Security Exchange Name NYSE
1.375% Notes due 2061  
Document Information [Line Items]  
Title of 12(b) Security 1.375% Notes due 2061
Trading Symbol LLY61
Security Exchange Name NYSE
XML 7 lly-20221012_htm.xml IDEA: XBRL DOCUMENT 0000059478 2022-10-12 2022-10-12 0000059478 us-gaap:CommonClassAMember 2022-10-12 2022-10-12 0000059478 lly:A718NotesDueJune12025Member 2022-10-12 2022-10-12 0000059478 lly:A1.625NotesDueJune22026Member 2022-10-12 2022-10-12 0000059478 lly:A2.125NotesDueJune32030Member 2022-10-12 2022-10-12 0000059478 lly:A625Notesdue2031Member 2022-10-12 2022-10-12 0000059478 lly:A500NotesDue2033Member 2022-10-12 2022-10-12 0000059478 lly:A6.77NotesDueJanuary12036Member 2022-10-12 2022-10-12 0000059478 lly:A1625NotesDue2043Member 2022-10-12 2022-10-12 0000059478 lly:A1.700Notesdue2049Member 2022-10-12 2022-10-12 0000059478 lly:A1125NotesDue2051Member 2022-10-12 2022-10-12 0000059478 lly:A1375NotesDue2061Member 2022-10-12 2022-10-12 0000059478 false 8-K 2022-10-12 ELI LILLY AND COMPANY IN 001-06351 35-0470950 Lilly Corporate Center Indianapolis, IN 46285 317 276-2000 false false false false Common Stock (no par value) LLY NYSE 7 1/8% Notes due 2025 LLY25 NYSE 1.625% Notes due 2026 LLY26 NYSE 2.125% Notes due 2030 LLY30 NYSE 0.625% Notes due 2031 LLY31 NYSE 0.500% Notes due 2033 LLY33 NYSE 6.77% Notes due 2036 LLY36 NYSE 1.625% Notes due 2043 LLY43 NYSE 1.700% Notes due 2049 LLY49A NYSE 1.125% Notes due 2051 LLY51 NYSE 1.375% Notes due 2061 LLY61 NYSE false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 12 22 1 false 11 0 false 0 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.lilly.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports lly-20221012.htm lly-20221012.xsd lly-20221012_def.xml lly-20221012_lab.xml lly-20221012_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "lly-20221012.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 12, "dts": { "definitionLink": { "local": [ "lly-20221012_def.xml" ] }, "inline": { "local": [ "lly-20221012.htm" ] }, "labelLink": { "local": [ "lly-20221012_lab.xml" ] }, "presentationLink": { "local": [ "lly-20221012_pre.xml" ] }, "schema": { "local": [ "lly-20221012.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 39, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 10, "memberStandard": 1, "nsprefix": "lly", "nsuri": "http://www.lilly.com/20221012", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lly-20221012.htm", "contextRef": "i0e346a1893ab45d085d94bf77bf7be08_D20221012-20221012", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.lilly.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lly-20221012.htm", "contextRef": "i0e346a1893ab45d085d94bf77bf7be08_D20221012-20221012", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 11, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationDateOfIncorporation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date when an entity was incorporated", "label": "Entity Incorporation, Date of Incorporation", "terseLabel": "Entity Incorporation, Date of Incorporation" } } }, "localname": "EntityIncorporationDateOfIncorporation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "lly_A1.625NotesDueJune22026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.625% Notes Due June 2, 2026 [Member]", "label": "1.625% Notes Due June 2, 2026 [Member]", "terseLabel": "1.625% Notes due 2026" } } }, "localname": "A1.625NotesDueJune22026Member", "nsuri": "http://www.lilly.com/20221012", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_A1.700Notesdue2049Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.700% Notes due 2049 [Member]", "label": "1.700% Notes due 2049 [Member]", "terseLabel": "1.700% Notes due 2049" } } }, "localname": "A1.700Notesdue2049Member", "nsuri": "http://www.lilly.com/20221012", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_A1125NotesDue2051Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.125% Notes due 2051", "label": "1.125% Notes due 2051 [Member]", "terseLabel": "1.125% Notes due 2051" } } }, "localname": "A1125NotesDue2051Member", "nsuri": "http://www.lilly.com/20221012", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_A1375NotesDue2061Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.375% Notes due 2061", "label": "1.375% Notes due 2061 [Member]", "terseLabel": "1.375% Notes due 2061" } } }, "localname": "A1375NotesDue2061Member", "nsuri": "http://www.lilly.com/20221012", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_A1625NotesDue2043Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.625% Notes due 2043", "label": "1.625% Notes due 2043 [Member]", "terseLabel": "1.625% Notes due 2043" } } }, "localname": "A1625NotesDue2043Member", "nsuri": "http://www.lilly.com/20221012", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_A2.125NotesDueJune32030Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.125% Notes Due June 3, 2030 [Member]", "label": "2.125% Notes Due June 3, 2030 [Member]", "terseLabel": "2.125% Notes due 2030" } } }, "localname": "A2.125NotesDueJune32030Member", "nsuri": "http://www.lilly.com/20221012", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_A500NotesDue2033Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": ".500% Notes due 2033", "label": ".500% Notes due 2033 [Member]", "terseLabel": ".500% Notes due 2033" } } }, "localname": "A500NotesDue2033Member", "nsuri": "http://www.lilly.com/20221012", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_A6.77NotesDueJanuary12036Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]", "label": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]", "terseLabel": "6.77% Notes due 2036" } } }, "localname": "A6.77NotesDueJanuary12036Member", "nsuri": "http://www.lilly.com/20221012", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_A625Notesdue2031Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": ".625% Notes due 2031 [Member]", "label": ".625% Notes due 2031 [Member]", "terseLabel": "0.625% Notes due 2031" } } }, "localname": "A625Notesdue2031Member", "nsuri": "http://www.lilly.com/20221012", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_A718NotesDueJune12025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "7 1/8% Notes Due June\u00a01, 2025 [Member]", "label": "7 1/8% Notes Due June\u00a01, 2025 [Member]", "terseLabel": "7 1/8% Notes due 2025" } } }, "localname": "A718NotesDueJune12025Member", "nsuri": "http://www.lilly.com/20221012", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Class A [Member]", "terseLabel": "Common Stock (no par value)" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0000059478-22-000233-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000059478-22-000233-xbrl.zip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